CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 2, 2018--
Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing
next-generation antibody-drug conjugate therapies for the treatment of
cancer, today announced that company management will present a corporate
overview at the Canaccord Genuity 38th Annual Growth
Conference on Thursday, Aug. 9, 2018 at 1:30 p.m. ET in Boston.
A live webcast of the company’s presentation will be accessible from the
Investors & Media section of Sesen Bio’s website, www.sesenbio.com.
An archived replay of the webcast will be available on the company's
website for 90 days after the conference.
About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical
company advancing next-generation antibody-drug conjugate therapies for
the treatment of cancer based on the company’s Targeted Protein
Therapeutics platform. The company’s lead program, Vicinium™, also known
as VB4-845, is currently in a Phase 3 registration trial, the VISTA
Trial, for the treatment of high-grade non-muscle invasive bladder
cancer. Vicinium incorporates a tumor-targeting antibody fragment and a
protein cytotoxic payload into a single protein molecule designed to
selectively and effectively kill cancer cells while sparing healthy
cells. For more information, please visit the company’s website at www.sesenbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180802005160/en/
Source: Sesen Bio, Inc.
THRUST Strategic Communications
Monique Allaire, 617-895-9511